A HER 1-2 punch: dual EGFR targeting deals resistance a deadly blow

Cancer Discov. 2014 Sep;4(9):991-4. doi: 10.1158/2159-8290.CD-14-0791.

Abstract

Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer.

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / antagonists & inhibitors*
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Male
  • Mutation*

Substances

  • ErbB Receptors